Informations générales (source: ClinicalTrials.gov)
A Prospective Randomized Controlled Study Comparing the Efficacy of Pelvic Floor Muscle Training and Oral Duloxetine in the Recovery of Continence After Robotic Assisted Radical Prostatectomy
Interventional
Phase 3
Institut Mutualiste Montsouris (Voir sur ClinicalTrials)
mai 2015
juin 2017
29 juin 2024
Objectives:
Primary: Comparison of proportion of patient achieving continence between the four arms
at 6 months.
Secondary:
- Comparison of time to achieve continence between the four arms.
- Comparison of urinary symptoms and quality of life improvement between the four
arms.
- Assessment of adverse events in Duloxetine arms.
Primary outcome/ time frame: Proportion of patient achieving continence at 6 months.
Continence is defined as "using no pad"or "only security pad".
Secondary outcome:
- time to achieve continence
- Quality of life tested in relation to incontinence according to Visual Analog Scale
(VAS) and King's Health Questionnaire (KQH).
- Urinary symptoms measured with International Prostate Symptom Score (IPSS).
No. of subjects entered: 300 patients informed and included, 240 patients will be
randomized.
Statistical methods
- Proportion of patients who achieve continence and time to achieve continence will be
compared between the four arms.
- Comparison of quality of life outcomes between the four arms
- Comparison of clinical variables that can affect the primary/secondary outcome -
univariate and multivariate analysis (ITT).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| INSTITUT MUTUALISTE MONTSOURIS | Contact (sur clinicalTrials) | ||||
Critères
Homme
Inclusion Criteria:
1. All consecutive patients undergoing Robotic Assisted Radical Prostatectomy for
clinically organ confined prostate cancer
1. All consecutive patients undergoing Robotic Assisted Radical Prostatectomy for
clinically organ confined prostate cancer
1. Prior urethral, bladder or prostate surgery
2. Pelvic radiotherapy.
3. Overactive bladder
4. Known neurological disease associated to LUTS
5. Hepatic impairment with hepatic insufficiency.
6. Severe renal impairment (creatinine clearance < 30ml/min)
7. Hypersensitivity to duloxetine
8. Uncontrolled hypertension
9. Narrow angle glaucoma
Post-operative criteria:
10. Post-void residual urine volume > 100ml measured 15 days after the RARP